Lansdowne Partners UK LLP Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Lansdowne Partners UK LLP bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 35,000 shares of the company’s stock, valued at approximately $1,455,000. Moderna comprises 0.1% of Lansdowne Partners UK LLP’s investment portfolio, making the stock its 17th biggest position.

Several other institutional investors also recently bought and sold shares of MRNA. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares in the last quarter. Venturi Wealth Management LLC increased its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares in the last quarter. Compass Planning Associates Inc purchased a new position in shares of Moderna in the 4th quarter valued at about $37,000. Crowley Wealth Management Inc. purchased a new position in Moderna during the fourth quarter worth approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB boosted its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MRNA shares. JPMorgan Chase & Co. reduced their target price on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, March 21st. Citigroup assumed coverage on shares of Moderna in a report on Thursday, March 13th. They set a “neutral” rating and a $40.00 price objective on the stock. Bank of America cut their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Finally, The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Moderna has an average rating of “Hold” and an average price target of $58.70.

Moderna Price Performance

NASDAQ:MRNA opened at $26.20 on Friday. The company’s 50-day moving average is $31.56 and its two-hundred day moving average is $41.01. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47. The firm has a market capitalization of $10.13 billion, a price-to-earnings ratio of -2.82 and a beta of 2.23.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.